WA-TANIUM
6.1.2022 21:41:12 CET | Business Wire | Press release
Industry experts are naming Log4j one of the most severe internet and computer vulnerabilities they have encountered. The United States Cyber Security and Infrastructure Security Agency (CISA) Director stated that the Log4j vulnerability: “…is one of the most serious I’ve seen in my entire career, if not the most serious.”
Log4j is the perfect storm of severity, pervasiveness, and ease of exploitability. It is an open-source code library widely used inside commercial and open-source software applications. The recently discovered vulnerability allows hackers to take complete control of affected endpoints with a single line of code. As a result, finding and fixing every single instance of Log4j and applications that rely on it is critical for corporate networks.
The key to finding all instances of Log4j is the ability to look inside every file in a corporate network and Tanium is the only solution that, in minutes, can look inside every file, and find every instance of Log4j, at scale today.
Tanium is supporting organizations globally in the eradication of Log4j vulnerabilities. The Tanium Platform uniquely enables organizations to manage their exposure by:
- Looking inside nested archive folders and files for vulnerabilities
- Finding references to Log4j even if they were renamed (maliciously or by design)
- Automating software upgrades and patches at scale to all vulnerable systems
- Watching, alerting, and remediating any new instance of the vulnerability that is inadvertently introduced post-cleanup
Ring Power Corp. was able to scan every file and folder and find every single instance of Log4j with their entire environment in only minutes. “Tanium Reveal has been critical to us in responding to Log4j. Nobody else was able to search for references to the impacted library in common file formats and detect instances of exploitation. With Tanium, we accomplished in 30 minutes what would have taken months.” - Kevin Bush, VP of IT at Ring Power Corp.
Salisbury University stated “We saw first-hand the strength of Tanium during the Log4j vulnerability crisis. Tanium made us aware of many endpoints that were vulnerable to Log4j through user-installed tools and applications that we weren’t aware of.” – Steven Blankenship, Director of IT
To set up a Tanium evaluation of your environment for the Log4j vulnerability, please contact us at https://www.tanium.com/log4j/ .
About Tanium
Tanium is the platform that the most demanding and complex organizations trust to gain visibility and control across all endpoints in on-premises, cloud and hybrid environments. Tanium addresses today’s increasing IT challenges with high fidelity endpoint data — giving IT operations, security and risk teams confidence to quickly manage, secure and protect their networks at scale. Nearly half of the Fortune 100, top retailers and financial institutions, and multiple branches of the U.S. Armed Forces trust Tanium to help see and control every endpoint, everywhere. That’s the power of certainty. Tanium has been named to the Forbes Cloud 100 list of “Top 100 Private Companies in Cloud Computing” for six consecutive years and ranks on FORTUNE’s list of the “Best Large Workplaces in Technology 2021.” Visit www.tanium.com and follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005859/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
